Empowered Patient Podcast

Dr. Paulo Garcia, CEO and Co-Founder of Kytopen, is developing systems to refine the types of payloads, including RNA, DNA, and CRISPR-Cas RMP, that can be delivered to primary T cells, primary Natural Killer cells, and CD34 stem cells. To maximize the number of successfully engineered cells, the Flowfect Discovery technology, using a non-viral approach, automates the process of cell engineering and gene delivery into cells while dramatically reducing the time to produce the cells. Paulo explains, "One of the key differentiating aspects of our technology is that we are using a continuous fluid flow format for the engineering of our cells. This fluid flow contributes to the delivery of these payloads to the different cells. And to put it into perspective, the flow rates that we use are quite large. They are in the tens of milliliters per minute. And if you translate that into a throughput of cells, you're talking about being able to process anywhere between 1 to 2 billion cells in 30 seconds. And these are lar